We speculate that in acquired TTP, wherein significant levels of autoantibodies to ADAMTS13 are present, dosing of the M5 variant mRNA may provide sustained levels of enzyme activity to decrease ULMW-vWF and prevent thrombotic microangiopathies. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.